Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
33 An international phase III RCT (RESOLVE-IT, NCT02704403) comparing elafibranor with placebo in NASH patients was terminated early due to insignificant efficacy but without significant adverse events at 72 weeks of treatment
I didn't know there was one So excited to get this
What the study showed The researchers performed a two-hour oral glucose tolerance test on 59 non-diabetic individuals with moderate to severe kidney disease and 39 controls
these include the patients in the reference population who did not have a diagnosis ( n = 69) or patients with IEMs that are not typically treated with l-carnitine supplementation (e.g., guanidinoacetate methyltransferase deficiency (OMIM612736
doi:10.1016/j.cmet.2022.07.013 Source for half-life approximately 6 days, once-weekly dosing pharmacokinetic rationale, and approximately 95% subcutaneous bioavailability
Available at: 5 Frank, RG, Garfield RL
US$ 21.14
US$ 28.20
US$ 20.71
US$ 28.34
US$ 20.48
US$ 23.19
